The pharmacology of itch

Ingram, John R.; Ahluwalia, Amrita

doi:10.1111/bph.14865

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[37][38][39] However, skin sensitivity, changes in skin appearance, pain or itching go far beyond the skin surface involving psychological factors and emotional distress. 39,40 We argue that a biopsychosocial approach is needed to ensure appropriate management of patients' symptoms. 41,42…”

Section: Discussionmentioning

confidence: 99%

Patient prioritisation of impact items to develop the patient‐reported impact of dermatological diseases (PRIDD) measure: European Delphi data

Trialonis‐Suthakharan,

Pattinson,

Tahmasebi Gandomkari

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundThe Global Research on the Impact of Dermatological Diseases (GRIDD) project is developing a patient‐reported measure of the impact of dermatological disease on the patient's life called Patient Reported Impact of Dermatological Diseases (PRIDD). We developed a list of 263 potential impact items through a global qualitative interview study with 68 patients. We next conducted a Delphi study to seek consensus on which of these items to prioritize for inclusion in PRIDD. This study aims to explore patterns in demographic (e.g. country) and clinical variables (e.g. disease group) across the impacts ranked as most important to European dermatology patients.MethodsWe conducted a modified, two rounds Delphi study, testing the outcomes from the previous qualitative interview study. Adults (≥18 years) living with a dermatological disease were recruited through the International Alliance of Dermatology Patient Organizations' (GlobalSkin) membership network. The survey consisted of a demographic questionnaire and 263 impact items and was available in six languages. Quantitative data were collected using ranking scales and analysed against a priori consensus criteria. Qualitative data were collected using free‐text responses and a Framework Analysis was conducted. European data were obtained, and descriptive statistics, including multiple subgroup analyses, were performed.ResultsOut of 1154 participants, 441 Europeans representing 46 dermatological disease from 25 countries participated. The results produced a list of the top 20 impacts reported by European patients, with psychological impacts accounting for the greatest proportion.ConclusionThis study identified what patients consider to be the most important issues impacting their lives as a result of their dermatological disease. The data support previous evidence that patients experience profound psychological impacts and require psychological support. The findings can inform research, clinical practice and policy by indicating research questions and initiatives that are of most benefit to patients.

show abstract